These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

314 related items for PubMed ID: 29624806

  • 21. Acquired Resistance Mechanisms to Combination Met-TKI/EGFR-TKI Exposure in Met-Amplified EGFR-TKI-Resistant Lung Adenocarcinoma Harboring an Activating EGFR Mutation.
    Yamaoka T, Ohmori T, Ohba M, Arata S, Kishino Y, Murata Y, Kusumoto S, Ishida H, Shirai T, Hirose T, Ohnishi T, Sasaki Y.
    Mol Cancer Ther; 2016 Dec; 15(12):3040-3054. PubMed ID: 27612490
    [Abstract] [Full Text] [Related]

  • 22. Enhanced anticancer effect of the combination of BIBW2992 and thymidylate synthase-targeted agents in non-small cell lung cancer with the T790M mutation of epidermal growth factor receptor.
    Takezawa K, Okamoto I, Tanizaki J, Kuwata K, Yamaguchi H, Fukuoka M, Nishio K, Nakagawa K.
    Mol Cancer Ther; 2010 Jun; 9(6):1647-56. PubMed ID: 20530710
    [Abstract] [Full Text] [Related]

  • 23. PLAUR Confers Resistance to Gefitinib Through EGFR/P-AKT/Survivin Signaling Pathway.
    Zhou J, Kwak KJ, Wu Z, Yang D, Li J, Chang M, Song Y, Zeng H, Lee LJ, Hu J, Bai C.
    Cell Physiol Biochem; 2018 Jun; 47(5):1909-1924. PubMed ID: 29961070
    [Abstract] [Full Text] [Related]

  • 24. Targeting Adenine Nucleotide Translocase-2 (ANT2) to Overcome Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in Non-Small Cell Lung Cancer.
    Jang JY, Kim YG, Nam SJ, Keam B, Kim TM, Jeon YK, Kim CW.
    Mol Cancer Ther; 2016 Jun; 15(6):1387-96. PubMed ID: 26883272
    [Abstract] [Full Text] [Related]

  • 25. Acquired MET Y1248H and D1246N Mutations Mediate Resistance to MET Inhibitors in Non-Small Cell Lung Cancer.
    Li A, Yang JJ, Zhang XC, Zhang Z, Su J, Gou LY, Bai Y, Zhou Q, Yang Z, Han-Zhang H, Zhong WZ, Chuai S, Zhang Q, Xie Z, Gao H, Chen H, Wang Z, Wang Z, Yang XN, Wang BC, Gan B, Chen ZH, Jiang BY, Wu SP, Liu SY, Xu CR, Wu YL.
    Clin Cancer Res; 2017 Aug 15; 23(16):4929-4937. PubMed ID: 28396313
    [Abstract] [Full Text] [Related]

  • 26. DDX17 nucleocytoplasmic shuttling promotes acquired gefitinib resistance in non-small cell lung cancer cells via activation of β-catenin.
    Li K, Mo C, Gong D, Chen Y, Huang Z, Li Y, Zhang J, Huang L, Li Y, Fuller-Pace FV, Lin P, Wei Y.
    Cancer Lett; 2017 Aug 01; 400():194-202. PubMed ID: 28259822
    [Abstract] [Full Text] [Related]

  • 27. FGL1 regulates acquired resistance to Gefitinib by inhibiting apoptosis in non-small cell lung cancer.
    Sun C, Gao W, Liu J, Cheng H, Hao J.
    Respir Res; 2020 Aug 10; 21(1):210. PubMed ID: 32778129
    [Abstract] [Full Text] [Related]

  • 28. Polyphyllin II Restores Sensitization of the Resistance of PC-9/ZD Cells to Gefitinib by a Negative Regulation of the PI3K/Akt/mTOR Signaling Pathway.
    Zheng R, Jiang H, Li J, Liu X, Xu H.
    Curr Cancer Drug Targets; 2017 Aug 10; 17(4):376-385. PubMed ID: 28093061
    [Abstract] [Full Text] [Related]

  • 29. Knockdown of the Bcl-2 gene increases sensitivity to EGFR tyrosine kinase inhibitors in the H1975 lung cancer cell line harboring T790M mutation.
    Zou M, Xia S, Zhuang L, Han N, Chu Q, Chao T, Peng P, Chen Y, Gui Q, Yu S.
    Int J Oncol; 2013 Jun 10; 42(6):2094-102. PubMed ID: 23588221
    [Abstract] [Full Text] [Related]

  • 30. Establishment of patient-derived non-small cell lung cancer xenograft models with genetic aberrations within EGFR, KRAS and FGFR1: useful tools for preclinical studies of targeted therapies.
    Zhang XC, Zhang J, Li M, Huang XS, Yang XN, Zhong WZ, Xie L, Zhang L, Zhou M, Gavine P, Su X, Zheng L, Zhu G, Zhan P, Ji Q, Wu YL.
    J Transl Med; 2013 Jul 10; 11():168. PubMed ID: 23842453
    [Abstract] [Full Text] [Related]

  • 31. Loss of histone lysine methyltransferase EZH2 confers resistance to tyrosine kinase inhibitors in non-small cell lung cancer.
    Quan C, Chen Y, Wang X, Yang D, Wang Q, Huang Y, Petersen RB, Liu X, Zheng L, Li Y, Huang K.
    Cancer Lett; 2020 Dec 28; 495():41-52. PubMed ID: 32920200
    [Abstract] [Full Text] [Related]

  • 32. TAZ sensitizes EGFR wild-type non-small-cell lung cancer to gefitinib by promoting amphiregulin transcription.
    Yuan W, Xu W, Li Y, Jiang W, Li Y, Huang Q, Chen B, Wu S, Wang Y, Song W, Zhao W, Wu J.
    Cell Death Dis; 2019 Mar 25; 10(4):283. PubMed ID: 30911072
    [Abstract] [Full Text] [Related]

  • 33. MiR-21 overexpression is associated with acquired resistance of EGFR-TKI in non-small cell lung cancer.
    Li B, Ren S, Li X, Wang Y, Garfield D, Zhou S, Chen X, Su C, Chen M, Kuang P, Gao G, He Y, Fan L, Fei K, Zhou C, Schmit-Bindert G.
    Lung Cancer; 2014 Feb 25; 83(2):146-53. PubMed ID: 24331411
    [Abstract] [Full Text] [Related]

  • 34. Targeted inhibition of c-MET by podophyllotoxin promotes caspase-dependent apoptosis and suppresses cell growth in gefitinib-resistant non-small cell lung cancer cells.
    Oh HN, Kwak AW, Lee MH, Kim E, Yoon G, Cho SS, Liu K, Chae JI, Shim JH.
    Phytomedicine; 2021 Jan 25; 80():153355. PubMed ID: 33039730
    [Abstract] [Full Text] [Related]

  • 35. EGFR and MET receptor tyrosine kinase-altered microRNA expression induces tumorigenesis and gefitinib resistance in lung cancers.
    Garofalo M, Romano G, Di Leva G, Nuovo G, Jeon YJ, Ngankeu A, Sun J, Lovat F, Alder H, Condorelli G, Engelman JA, Ono M, Rho JK, Cascione L, Volinia S, Nephew KP, Croce CM.
    Nat Med; 2011 Dec 11; 18(1):74-82. PubMed ID: 22157681
    [Abstract] [Full Text] [Related]

  • 36. PA-MSHA in combination with EGFR tyrosine kinase inhibitor: A new strategy to overcome the drug resistance of non-small cell lung cancer cells.
    Zhao XM, Pan SY, Huang QL, Lu YN, Wu XH, Chang JH, Liu ZB, Cai XW, Liu Q, Wang JL, Fu XL.
    Oncotarget; 2016 Aug 02; 7(31):49384-49396. PubMed ID: 27283902
    [Abstract] [Full Text] [Related]

  • 37. The long non-coding RNA, GAS5, enhances gefitinib-induced cell death in innate EGFR tyrosine kinase inhibitor-resistant lung adenocarcinoma cells with wide-type EGFR via downregulation of the IGF-1R expression.
    Dong S, Qu X, Li W, Zhong X, Li P, Yang S, Chen X, Shao M, Zhang L.
    J Hematol Oncol; 2015 Apr 29; 8():43. PubMed ID: 25925741
    [Abstract] [Full Text] [Related]

  • 38. Overexpression of OCT4 is associated with gefitinib resistance in non-small cell lung cancer.
    Li B, Yao Z, Wan Y, Lin D.
    Oncotarget; 2016 Nov 22; 7(47):77342-77347. PubMed ID: 27816965
    [Abstract] [Full Text] [Related]

  • 39. USP8 is a novel target for overcoming gefitinib resistance in lung cancer.
    Byun S, Lee SY, Lee J, Jeong CH, Farrand L, Lim S, Reddy K, Kim JY, Lee MH, Lee HJ, Bode AM, Won Lee K, Dong Z.
    Clin Cancer Res; 2013 Jul 15; 19(14):3894-904. PubMed ID: 23748694
    [Abstract] [Full Text] [Related]

  • 40. IRS4 promotes the progression of non-small cell lung cancer and confers resistance to EGFR-TKI through the activation of PI3K/Akt and Ras-MAPK pathways.
    Hao P, Huang Y, Peng J, Yu J, Guo X, Bao F, Dian Z, An S, Xu TR.
    Exp Cell Res; 2021 Jun 15; 403(2):112615. PubMed ID: 33894221
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 16.